Dermatitis, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 5, 2024
Some patients with atopic dermatitis (AD) do not sufficiently respond to upadacitinib, a Janus kinase 1 inhibitor. However, predictive factors for nonresponders remain unclear in real-world practice.
Language: Английский
Dermatology and Therapy, Journal Year: 2024, Volume and Issue: 14(8), P. 1983 - 2038
Published: July 16, 2024
The risk of infections associated with biological drugs (BD) and Janus kinase inhibitors (JAKi) has been extensively explored in the literature. However, there is a dearth studies that evaluate both pharmacological groups together and, furthermore, compare them. Here, we review BD JAKi used dermatology.
Language: Английский
Citations
8
Dermatitis, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 3, 2024
Tralokinumab, a monoclonal anti-IL-13 antibody, is approved for treating atopic dermatitis (AD). Real-world data on its effectiveness and safety are limited.
Language: Английский
Citations
8
Clinical and Experimental Dermatology, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 3, 2024
Abstract Psoriasis is a chronic, complicated inflammatory skin disease. Genital, nail and scalp lesions with psoriasis are difficult to treat can considerably impair patients’ quality of life (QoL). Deucravacitinib, an oral selective tyrosine kinase 2 inhibitor, may represent novel therapeutic option that could improve these challenging manifestations. To investigate this, we conducted retrospective study between January 2023 February 2024, involving 70 patients treated deucravacitinib 6 mg orally once daily for 24 weeks. We evaluated how many achieved static Physician’s Global Assessment (PGA) Genitalia (sPGA-GTM) score clear/almost clear (0/1), PGA Fingernail (PGA-F) 0/1, scalp-specific (ss-PGA) (sPGA) 0/1 Dermatology Life Quality Index at weeks 4, 16 24. also assessed the Area Severity scores. Deucravacitinib improved genital, lesions, as well systemic eruption QoL in psoriasis. be promising treatment difficult-to-treat areas
Language: Английский
Citations
5
BMC Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: Jan. 21, 2025
Despite the well-documented immune dysregulation in both psoriasis and Sjögren's syndrome (SS), specific link between these two autoimmune diseases has not been extensively explored. The present study aims to investigate impact of on risk SS. A retrospective cohort using TriNetX data compared SS development patients with controls propensity score matching, Kaplan–Meier curves, Cox models. Transcriptome were analyzed identify shared differentially expressed genes pathways diseases. total 293,905 an equal number individuals without included. After baseline characteristics groups balanced. During follow-up period, 3339 1937 developed curves indicated a significantly higher developing group non-psoriasis group. Upon adjustment for multiple confounding factors, was 50% than (hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.42–1.58). Subgroup analyses confirmed elevated associated psoriasis. Patients psoriatic arthritis (PsA) those treated biological agents had even Transcriptomic analysis revealed potential pathogenesis involving cellular proliferation, cell recruitment, cytokine secretion, interferon response viral infections. Psoriasis might increase SS, which is augmented by PsA. overlapping immunological mechanisms may underlie co-occurrence
Language: Английский
Citations
0
The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 28, 2025
Abstract Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long‐term real‐world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study aimed to evaluate 52‐week of deucravacitinib in psoriasis patients, (≥65 years vs <65 years) BMI (≥25 <25). A prospective was conducted from December 2022 August 2024, involving 107 Japanese patients aged ≥15 with moderate severe Patients received 6 mg daily 52 weeks. Therapeutic evaluated the achievement rates Psoriasis Area Severity Index (PASI) 75, PASI 90, 100, other key clinical indices. Data were BMI. Mean scores decreased until week similarly all patients’ groups or The 100 at 86.36%, 59.09%, 13.64% ≥65 years, while they 65.22%, 39.13% respectively, showing a slightly lower rate years. 81.82%, 73.33%, 18.18% ≥25, 88.24%, 82.86%, 29.41% < 25, these weeks 4, 16, 24, 40 ≥25. Deucravacitinib improved indices during period patients' present results indicate that may be elderly as well younger middle‐aged ≥25 compared those 25.
Language: Английский
Citations
0
The Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 7, 2025
Abstract Real‐world evidence on the long‐term effectiveness of deucravacitinib, a selective tyrosine kinase 2 inhibitor for psoriasis, remains limited, particularly in patients with different histories systemic treatments. We evaluated 52‐week deucravacitinib stratified by history apremilast or biologic usage. This prospective, single‐center study included 110 moderate‐to‐severe psoriasis who received daily (6 mg). Psoriasis Area and Severity Index (PASI) Dermatology Life Quality (DLQI) scores during treatment were analyzed subgroups Deucravacitinib decreased PASI DLQI 52 weeks patients, both without prior The percent reductions from baseline at week similar apremilast‐experienced (92% 77.9%) apremilast‐naive (88.3% 81.6%), respectively. achievement rates 100 absolute ≤1 (30.8% 61.5%) slightly higher than those (20.5% 46.2%). biologic‐naive (91.6 82.8%) biologic‐experienced (57.6% 63.6%), 75, (84.4%, 24.4%, 53.3%) (57.1%, 14.3%, 28.6%), generated sustained diverse patient subgroups, supporting its role as universal psoriasis.
Language: Английский
Citations
0
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1746 - 1746
Published: March 5, 2025
Deucravacitinib, a selective oral tyrosine kinase 2 (TYK2) inhibitor, has demonstrated strong efficacy in the treatment of moderate-to-severe psoriasis. It works through an allosteric mechanism to selectively inhibit TYK2, leading suppression IL-23/Th17/IL-17 axis and reduction key pro-inflammatory cytokines such as IL-17A, IL-17F, IL-22, IL-23. This review focuses on clinical implications deucravacitinib East Asian patients, highlighting its efficacy, safety, differences outcomes compared other populations. Data from pivotal trials POETYK PSO-3 PSO-4, which included populations, robust safety profiles, often surpassing results observed global like PSO-1 PSO-2. Subgroup analyses network meta-analyses further corroborate these findings, providing comprehensive understanding therapeutic potential this demographic. Factors lower body mass index, genetic predispositions, environmental influences may contribute response. The profile is favorable, with low rates serious adverse events stable laboratory parameters. underscores need for research investigate genetic, metabolic, factors that influence outcomes, aiming optimize personalized strategies patients
Language: Английский
Citations
0
Journal of Dermatological Treatment, Journal Year: 2025, Volume and Issue: 36(1)
Published: May 7, 2025
Psoriasis impacts patients' mental and physical health, prompting interest in psychosocial interventions. To compare rank different interventions for psoriasis their effects on well-being health. A systematic search was conducted using Cochrane Library, EMBASE, Medline, PsycINFO (via the OVID) from inception to 6 February 2024. Trials investing therapy patients were included random-effects network meta-analysis (NMW) within a Bayesian framework focusing dermatology life quality index (DLQI), depression, anxiety, along with adherence treatment. The risk of bias assessed by Handbook. Thirteen studies treatments 1233 included. low. For DLQI, 9 eligible, mindfulness + treatment as usual (TAU) better than TAU (MD = -7.21, 95%CI [-14.89, 0.54]). Cognitive behavioral (CBT) more effective improving HADS-anxiety -2.17, [-3.86, -0.49]) HADS-depression -1.58, [-3.65, 0.68]). Regarding adherence, CBT 0.84, [-0.62, 2.27]) ranked first, followed motivational interviewing TAU. We confirmed effectiveness health recommended several clinical practice. However, results should be cautiously interpreted, due lacking high-quality replication studies.
Language: Английский
Citations
0
The Journal of Dermatology, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 26, 2024
The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors high responses to have not been examined in a real-world clinical study. Our study aimed identify responders deucravacitinib. Therefore, retrospective was conducted on 74 patients with psoriasis treated (6 mg/day) at week 16 of treatment from January 2023 February 2024. Patients were classified into (achievers static Physician's Global Assessment [sPGA] 0 or 1 ≥2-point improvement basal sPGA) and non-responders (non-achievers). We compared baseline values laboratory indexes between non-responders. Multivariate logistic regression analysis used variables predicting responders. Forty-one (55.4%) considered as 16. revealed that the response associated higher age (odds ratio [OR] 1.04; 95% confidence interval [CI] 1.01-1.08; p = 0.0222) lower body mass index (BMI) (OR 0.825; CI 0.713-0.955; 0.0101). Higher BMI may predict treatment.
Language: Английский
Citations
3
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: Nov. 1, 2024
Psoriasis mimics uric acid in terms of inflammation, but the association has not been well defined. This study aimed to identify causal link between serum (SUA) and psoriasis an observational using National Health Nutrition Examination Survey (NHANES, 2004-2006, 2011-2014) transethnic Mendelian randomization (MR) analyses. We utilized weighted multivariable-adjusted logistic regression MR European East Asian populations assess association. Inverse variance (IVW) was main analysis. To test robustness pleiotropy, further sensitivity analyses were also conducted. Weighted analysis suggested that SUA positively related risk (OR = 1.339, 95% CI: 1.092-1.642, P 0.006) women. For all participants males, neither significant. IVW showed levels significantly associated with Europeans 1.099, 0.963-1.254, 0.159) or Asians 1.297, 0.576-2.918, 0.528). Furthermore, confirmed present results. In females, correlated; findings from did indicate a relationship psoriasis.
Language: Английский
Citations
1